Subscribe to our Newsletters !!
Few developments in science and technology have be
Worldwide, millions of workers handle chemicals us
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
French drugmaker Sanofi and its British peer GSK have begun a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical firms race to develop treatments against the coronavirus pandemic. Sanofi and GSK said in a joint statement on Thursday they’d begun the”Stage 1/2″ trial for their adjuvanted COVID-19 vaccine, and that they expect to make available across the world. This vaccine candidate utilizes the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines with GSK’s recognized pandemic adjuvant technology.
